BR112014026307A2 - preparação injetável - Google Patents

preparação injetável

Info

Publication number
BR112014026307A2
BR112014026307A2 BR112014026307A BR112014026307A BR112014026307A2 BR 112014026307 A2 BR112014026307 A2 BR 112014026307A2 BR 112014026307 A BR112014026307 A BR 112014026307A BR 112014026307 A BR112014026307 A BR 112014026307A BR 112014026307 A2 BR112014026307 A2 BR 112014026307A2
Authority
BR
Brazil
Prior art keywords
injectable preparation
present
viscosity
range
point
Prior art date
Application number
BR112014026307A
Other languages
English (en)
Other versions
BR112014026307B1 (pt
Inventor
Kaneko Daiki
Matsuda Takakuni
Hoshika Yusuke
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014026307(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112014026307A2 publication Critical patent/BR112014026307A2/pt
Publication of BR112014026307B1 publication Critical patent/BR112014026307B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "preparação injetável". a presente invenção refere-se ao fornecimento de uma preparação injetável estável em estocagem incluindo uma composição contendo um fármaco pouco solúvel como um ingrediente ativo e um meio de dispersão. outro objeto da presente invenção é prover uma seringa leve previamente cheia, pelo enchimento da seringa com a preparação injetável. a presente invenção provê uma preparação injetável incluindo uma composição contendo um fármaco pouco solúvel, um meio de dispersão, e um agente de suspensão específico, a composição tendo uma viscosidade de 40 pascal-segundos ou mais em pelo menos um ponto na faixa de taxas de cisalhamento de 0,01 a 0,02 s-1 e tendo uma viscosidade de 0,2 pascal-segundos ou menos em pelo menos um ponto na faixa de taxas de cisalhamento de 900 a 1000 s-1, conforme medição.
BR112014026307-8A 2012-04-23 2013-04-23 Preparações injetáveis compreendendo uma composição contendo um fármaco pouco solúvel,composição em gel, seu método de produção e seu uso,método para produção de uma seringa previamente cheia com uma composição em gel, seringa previamente cheia, e kit BR112014026307B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261636938P 2012-04-23 2012-04-23
US61/636,938 2012-04-23
US201361792089P 2013-03-15 2013-03-15
US61/792,089 2013-03-15
PCT/JP2013/062683 WO2013162048A1 (en) 2012-04-23 2013-04-23 Injectable preparation

Publications (2)

Publication Number Publication Date
BR112014026307A2 true BR112014026307A2 (pt) 2017-06-27
BR112014026307B1 BR112014026307B1 (pt) 2022-10-11

Family

ID=48614096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026307-8A BR112014026307B1 (pt) 2012-04-23 2013-04-23 Preparações injetáveis compreendendo uma composição contendo um fármaco pouco solúvel,composição em gel, seu método de produção e seu uso,método para produção de uma seringa previamente cheia com uma composição em gel, seringa previamente cheia, e kit

Country Status (32)

Country Link
US (8) US20150093442A1 (pt)
EP (2) EP3539534A1 (pt)
JP (6) JP6234996B2 (pt)
KR (3) KR102498075B1 (pt)
CN (3) CN114344259B (pt)
AR (1) AR090776A1 (pt)
AU (5) AU2013253374B2 (pt)
BR (1) BR112014026307B1 (pt)
CA (2) CA3120297A1 (pt)
CO (1) CO7151500A2 (pt)
CY (1) CY1122252T1 (pt)
DK (1) DK2841054T4 (pt)
EA (1) EA026619B1 (pt)
ES (1) ES2743706T5 (pt)
HK (2) HK1206988A1 (pt)
HR (1) HRP20191366T4 (pt)
HU (1) HUE045979T2 (pt)
IL (1) IL235299B (pt)
JO (2) JOP20200109A1 (pt)
LT (1) LT2841054T (pt)
MX (1) MX359241B (pt)
MY (2) MY198007A (pt)
NZ (1) NZ630335A (pt)
PH (2) PH12014502379A1 (pt)
PL (1) PL2841054T5 (pt)
PT (1) PT2841054T (pt)
SG (3) SG10201608753UA (pt)
SI (1) SI2841054T2 (pt)
TW (4) TW202313036A (pt)
UA (1) UA115444C2 (pt)
WO (1) WO2013162048A1 (pt)
ZA (1) ZA201407335B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
CN105461703B (zh) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 一种brexpiprazole的制备方法
JP6513461B2 (ja) * 2015-04-14 2019-05-15 帝國製薬株式会社 ブレクスピプラゾールの経皮吸収製剤
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
WO2017134038A1 (en) * 2016-02-01 2017-08-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
JP6901571B2 (ja) * 2017-01-26 2021-07-14 四川瀛瑞医薬科技有限公司Ｓｉｃｈｕａｎ Ｙｉｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｍｐａｎｙ ナノ炭素−鉄複合システム及びその組成物、調製方法並びに使用
WO2019213286A1 (en) * 2018-05-02 2019-11-07 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
WO2020089942A2 (en) * 2018-11-02 2020-05-07 Amaterasu Lifesciences Llp A liquid injectable composition
US20230310417A1 (en) * 2020-03-30 2023-10-05 Cipla Limited Injectable aripiprazole formulation
CA3163321C (en) * 2020-04-01 2023-12-19 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
US20230372317A1 (en) * 2020-10-27 2023-11-23 Pts Consulting, Llc A liquid injectable composition of donepezil
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US11910794B2 (en) 2021-03-08 2024-02-27 Monsanto Technology Llc Solutions and methods for long-term pollen storage
WO2023067664A1 (ja) * 2021-10-18 2023-04-27 大塚製薬株式会社 ベンゾチオフェン化合物の新規結晶形及びその製造方法
WO2023240971A1 (zh) * 2022-06-16 2023-12-21 江苏慧聚药业股份有限公司 药物组合物及依匹哌唑口溶膜

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864100A (en) * 1957-04-09 1961-03-29 Pfizer & Co C Therapeutic pencillin compositions and the preparation thereof
JPS5913714A (ja) 1982-07-13 1984-01-24 Taito Pfizer Kk 外用消炎鎮痛剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
PE20030445A1 (es) * 2001-09-25 2003-07-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2003171264A (ja) * 2001-12-07 2003-06-17 Taiyo Yakuhin Kogyo Kk マイクロカプセル及びその製造方法
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
US7115587B2 (en) * 2002-08-20 2006-10-03 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
CA2511619C (en) 2002-12-27 2011-07-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
DE60302139T3 (de) 2003-01-09 2011-02-24 Otsuka Pharmaceutical Co., Ltd. Verfahren zur herstellung von aripiprazole
US7658998B2 (en) 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
CA2523484A1 (en) * 2003-05-02 2004-11-11 Rimon Therapeutics Ltd. Thermally reversible implant
MXPA05012538A (es) 2003-05-23 2006-02-22 Otsuka Pharma Co Ltd Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo.
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
PT1675573E (pt) * 2003-10-23 2008-12-30 Otsuka Pharma Co Ltd Formulação de iripiprazole injectável estéril de libertação controlada e um processo para a sua preparação
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
EP2633853A1 (en) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
JP2006219380A (ja) * 2005-02-08 2006-08-24 Minofuaagen Seiyaku:Kk グリチルリチン皮下注射製剤
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP2279727A3 (en) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
WO2007061896A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
JP4373983B2 (ja) 2006-01-27 2009-11-25 三菱電機インフォメーションシステムズ株式会社 流通経路管理装置及び流通経路管理プログラム
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
KR20090094811A (ko) * 2006-10-05 2009-09-08 파나세아 바이오테크 리미티드 새로운 형태의 주입형 데포조성물 및 이를 조제하기 위한 방법
JP4540700B2 (ja) 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
US20100151459A1 (en) 2007-01-26 2010-06-17 Jun Soo Kwon Marker for detecting the proposed efficacy of treatment
ES2529746T3 (es) 2007-06-25 2015-02-25 Otsuka Pharmaceutical Co., Ltd. Microesferas con una estructura de núcleo/cáscara
RU2483711C2 (ru) 2007-07-31 2013-06-10 Оцука Фармасьютикал Ко., Лтд. Способы получения суспензии арипипразола и лиофилизированного состава
WO2009026473A2 (en) * 2007-08-21 2009-02-26 Hollis-Eden Pharmaceuticals, Inc. Stabilized therapeutic compositions and formulations
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
JP2009286740A (ja) 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
TR200809200A1 (tr) 2008-12-01 2009-12-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Meloksikam içeren farmasötik formülasyonlar
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
NZ599227A (en) 2009-09-11 2014-02-28 Otsuka Pharma Co Ltd Therapeutic agent for chronic pain
BR112012028368B8 (pt) * 2010-08-24 2022-07-19 Otsuka Pharma Co Ltd Processo para prevenção de aglomeração de partículas de ingrediente ativo em uma suspensão, suspensão e composição de torta contendo derivado carbo estirila e óleo de silicone e/ou derivado de óleo de silicone
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
AR083884A1 (es) 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
JP2012121850A (ja) 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
HUE055836T2 (hu) 2011-01-24 2021-12-28 Otsuka Pharma Co Ltd Aripiprazolt hatóanyagként tartalmazó pogácsakészítményt tartalmazó orvostechnikai eszköz és aripiprazolt hatóanyagként tartalmazó pogácsakészítmény
AR085840A1 (es) 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
JP6034377B2 (ja) * 2011-06-27 2016-11-30 シャンハイ チョンシ ファーマシューティカル コーポレイション アリピプラゾール医薬製剤及びその調製方法
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
BR112014001520B1 (pt) 2011-07-28 2022-05-10 Otsuka Pharmaceutical Co., Ltd Processo para a produção de composto de benzo[b]tiofeno
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI679977B (zh) 2011-10-19 2019-12-21 大塚製藥股份有限公司 口服溶液
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JP2013139441A (ja) 2011-12-28 2013-07-18 Otsuka Pharmaceut Co Ltd マイクロスフェア
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
ES2743706T5 (es) 2022-05-25
US10517951B2 (en) 2019-12-31
PH12014502379B1 (en) 2015-01-12
CY1122252T1 (el) 2020-11-25
KR20210116702A (ko) 2021-09-27
AU2017228608A1 (en) 2017-10-05
CA2869889C (en) 2021-07-20
TWI637752B (zh) 2018-10-11
DK2841054T4 (da) 2022-06-13
EP2841054B1 (en) 2019-06-26
AU2020204200B2 (en) 2022-06-30
CN104470499B (zh) 2018-03-16
HK1257028A1 (zh) 2019-10-11
WO2013162048A1 (en) 2013-10-31
JP6470378B2 (ja) 2019-02-13
EP2841054B2 (en) 2022-04-06
EP2841054A1 (en) 2015-03-04
CA2869889A1 (en) 2013-10-31
US20180055941A1 (en) 2018-03-01
US11638757B2 (en) 2023-05-02
PH12019500498A1 (en) 2020-03-02
JP2015514751A (ja) 2015-05-21
TW201350136A (zh) 2013-12-16
US20200179517A1 (en) 2020-06-11
LT2841054T (lt) 2019-09-10
TW201900174A (zh) 2019-01-01
EA026619B1 (ru) 2017-04-28
KR102138852B1 (ko) 2020-07-28
MY178573A (en) 2020-10-16
JP2022050619A (ja) 2022-03-30
AU2020204200A1 (en) 2020-07-16
US20230390399A1 (en) 2023-12-07
JO3632B1 (ar) 2020-08-27
SI2841054T1 (sl) 2019-09-30
SG11201406451SA (en) 2014-11-27
HK1206988A1 (en) 2016-01-22
CN114344259B (zh) 2024-02-13
MX359241B (es) 2018-09-20
AR090776A1 (es) 2014-12-03
CA3120297A1 (en) 2013-10-31
US20190336607A1 (en) 2019-11-07
CO7151500A2 (es) 2014-12-29
IL235299A0 (en) 2014-12-31
KR102498075B1 (ko) 2023-02-10
AU2013253374A1 (en) 2014-10-23
US20190099494A1 (en) 2019-04-04
KR20200064173A (ko) 2020-06-05
JP6234996B2 (ja) 2017-11-22
JP2019070028A (ja) 2019-05-09
HRP20191366T1 (hr) 2019-12-27
AU2013253374B2 (en) 2017-06-15
KR20150003861A (ko) 2015-01-09
JP7293412B2 (ja) 2023-06-19
AU2017228608B2 (en) 2018-10-18
MY198007A (en) 2023-07-25
EA201491685A1 (ru) 2015-04-30
CN108186556B (zh) 2022-06-10
SG10201608753UA (en) 2016-12-29
TW202126303A (zh) 2021-07-16
AU2019200060A1 (en) 2019-01-31
CN108186556A (zh) 2018-06-22
US20220096638A1 (en) 2022-03-31
US20150093442A1 (en) 2015-04-02
PL2841054T3 (pl) 2019-10-31
EP3539534A1 (en) 2019-09-18
IL235299B (en) 2019-12-31
PL2841054T5 (pl) 2022-07-18
TW202313036A (zh) 2023-04-01
TWI713826B (zh) 2020-12-21
ZA201407335B (en) 2019-06-26
SI2841054T2 (sl) 2022-05-31
ES2743706T3 (es) 2020-02-20
DK2841054T3 (da) 2019-09-09
BR112014026307B1 (pt) 2022-10-11
JP2021008512A (ja) 2021-01-28
UA115444C2 (uk) 2017-11-10
HUE045979T2 (hu) 2020-01-28
JP2023113806A (ja) 2023-08-16
HRP20191366T4 (hr) 2022-08-19
NZ630335A (en) 2016-07-29
PH12014502379A1 (en) 2015-01-12
SG10201913425VA (en) 2020-03-30
CN104470499A (zh) 2015-03-25
PT2841054T (pt) 2019-09-09
JP2018048179A (ja) 2018-03-29
CN114344259A (zh) 2022-04-15
US11097007B2 (en) 2021-08-24
AU2022241491A1 (en) 2022-10-20
MX2014012811A (es) 2015-05-07
JOP20200109A1 (ar) 2017-06-16
US20210085794A1 (en) 2021-03-25
AU2017228608C1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
BR112014026307A2 (pt) preparação injetável
BR112015013774A2 (pt) membrana de hidrogel para prevenção de adesão
BR112014027116A2 (pt) formulação de anticorpo
BR112015002421A2 (pt) composição farmacêutica ou nutracêutica com características de liberação sustentada e com resistência contra a influência do etanol
BR112014013695A2 (pt) composição estabilizante de atrito simultâneo tendo uma resistência gel superior
BR112015014654A2 (pt) solubilizado de curcumina
BR112013018664A2 (pt) dispositivo médico que contém uma composição de torta que compreende aripiprazol como um ingrediente ativo, e uma composição de torta que compreende aripiprazol como um ingrediente ativo
BR112015014480A2 (pt) composições estáveis contendo íons metálicos
BR112014012522A2 (pt) método para encher um reservatório, reservatório e conjunto para encher um reservatório
BR112014032695A2 (pt) formulações estáveis para injeção parenteral de fármacos de pequenas moléculas
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
EA202091755A1 (ru) Композиции гиалуроновой кислоты, включающие мепивакаин
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
BR112015015408A2 (pt) composição de revestimento, e, artigo revestido
AR095428A1 (es) Composición de hidratos de carbono con fibra
AR085527A1 (es) Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
BR112014020262A8 (pt) Composição lubrificante que inclui copolímero esterificado e baixos níveis de agentes de dispersão, adequada para aplicações a sistemas de transmissão
PH12015502497A1 (en) Adhesion preventing material
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120
BR112021019903A2 (pt) Composição farmacêutica aquosa, uso da composição farmacêutica aquosa e método de produção de uma composição farmacêutica aquosa
BR112016021656A2 (pt) inibidores das vias de sinalização de wnt
BR112014015841A8 (pt) composição de resina alquídica compreendendo sílica
AR093802A1 (es) Relleno estable al horneado que contiene microparticulas
BR112014016308A8 (pt) composições de cuidados pessoais com pectinas acidificadas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2013, OBSERVADAS AS CONDICOES LEGAIS